AngioDynamics to Participate in the UBS Global Healthcare Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the medical technology sector, has announced its participation in the upcoming UBS Global Healthcare Conference. The event is scheduled for November 10, 2025, at 8:00 a.m. ET, where President and Chief Executive Officer Jim Clemmer, alongside Executive Vice President and Chief Financial Officer Stephen Trowbridge, will engage in a fireside chat. This forum offers a strategic platform for the executives to discuss the company’s innovative contributions to healthcare, particularly in restoring healthy blood flow within the vascular system and enhancing cancer treatment modalities.

The discussion is set to delve into AngioDynamics’ commitment to addressing significant patient needs through its advanced technologies and medical devices. The company's focus on improving the quality of life for patients has made it a favored choice among skilled physicians operating in dynamic healthcare markets. By harnessing innovative solutions, AngioDynamics aims to tackle unmet medical needs effectively.

Investors and attendees interested in the insights shared during the chat can access a live webcast via the “Investors” section on the company’s official website, www.angiodynamics.com. Following the event, a replay will also be made available, ensuring broader access to the valuable content presented.

The UBS Global Healthcare Conference serves as a vital forum where industry leaders gather to discuss the evolving landscape of healthcare and view how companies like AngioDynamics are positioning themselves for future growth and enhanced patient outcomes. For further inquiries or information, interested parties can reach out to Stephen Trowbridge, AngioDynamics’ Executive Vice President and CFO, at (518) 795-1408. For more details about AngioDynamics and its offerings, visit www.angiodynamics.com.

As AngioDynamics, Inc. (NASDAQ: ANGO) prepares to participate in the UBS Global Healthcare Conference on November 10, 2025, it presents an opportune moment for investors to reassess their position in this innovative medical technology company. AngioDynamics is focused on key growth areas: restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life. Together, these objectives align with significant healthcare trends and rising demand for effective medical solutions.

As the healthcare sector continues to grow, driven by an aging population and increasing incidences of chronic diseases, AngioDynamics is strategically positioned to benefit from these trends. The company's commitment to developing innovative technologies to address unmet patient needs resonates in fast-growing healthcare markets. Participation in high-profile conferences like UBS enhances visibility among investors and may facilitate strategic partnerships and investment interest, contributing to potential stock appreciation.

From a market perspective, AngioDynamics' forward-looking initiatives—coupled with a robust presentation at the conference—will likely provide clarity on the company's business strategy and growth prospects. Investors should watch for key insights regarding recent technological advancements, pipeline developments, and management’s vision for navigating evolving market dynamics.

It is essential for investors to consider not just current financial metrics but also long-term growth potential driven by innovative product offerings and market positioning. Given the ongoing developments in healthcare technology, AngioDynamics presents a compelling opportunity for investment that aligns with broader industry growth trends. Keeping abreast of developments from the UBS Conference will be crucial for informed investment decisions regarding ANGO. Monitoring company announcements and market reactions in the days following this event may yield valuable insights for potential entry points into this stock.